Cirrhosis and complications hepatocellular carcinoma – expanding indications for immunotherapy DOI
Helena Degroote

Acta Clinica Belgica, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 7

Published: Jan. 15, 2025

The incidence of hepatocellular carcinoma (HCC) is rising, with a shift towards Metabolic Dysfunction-associated Steatotic Liver Disease becoming the dominant risk factor in Western countries. Significant advances treatment have broadened range available therapeutic options. For this reason, clinical decision-making, along multidisciplinary team approach, plays crucial role improving patient outcomes. Following several landmark trials, immune checkpoint inhibitor-based therapy has now become established first-line standard care for advanced HCC. Additionally, application immunotherapy shifting to include patients earlier stages Research on combination locoregional therapies intermediate-stage HCC recently reported positive results, and other phase III trials same population early-stage are currently progress. Furthermore, growing number reports support safety efficacy immunotherapeutic agents as potential adjuncts downstaging HCC, thus facilitating successful liver transplantation. We will discuss published ongoing expanding field different

Language: Английский

Exploring treatment options in cancer: Tumor treatment strategies DOI Creative Commons
Beilei Liu, Hongyu Zhou, Licheng Tan

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: July 17, 2024

Traditional therapeutic approaches such as chemotherapy and radiation therapy have burdened cancer patients with onerous physical psychological challenges. Encouragingly, the landscape of tumor treatment has undergone a comprehensive remarkable transformation. Emerging fervently pursued modalities are small molecule targeted agents, antibody-drug conjugates (ADCs), cell-based therapies, gene therapy. These cutting-edge not only afford personalized precise targeting, but also provide enhanced comfort potential to impede disease progression. Nonetheless, it is acknowledged that these strategies still harbour untapped for further advancement. Gaining understanding merits limitations holds promise offering novel perspectives clinical practice foundational research endeavours. In this review, we discussed different modalities, including drugs, peptide antibody cell therapy, It will detailed explanation each method, addressing their status development, challenges, solutions. The aim assist clinicians researchers in gaining deeper diverse options, enabling them carry out effective advance more efficiently.

Language: Английский

Citations

175
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study DOI
Zhi‐Cheng Jin, Jian-Jia Chen, Xiaoli Zhu

et al.

EClinicalMedicine, Journal Year: 2024, Volume and Issue: 72, P. 102622 - 102622

Published: May 6, 2024

Language: Английский

Citations

47
Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape DOI Open Access

Emily N. Kinsey,

Hannah M. Lee

Cancers, Journal Year: 2024, Volume and Issue: 16(3), P. 666 - 666

Published: Feb. 4, 2024

Liver cancer is the third most common cause of cancer-related deaths worldwide, and hepatocellular carcinoma (HCC) makes up majority liver cases. Despite stabilization incidence rates in recent years due to effective viral hepatitis treatments, as well improved outcomes from early detection treatment advances, burden HCC anticipated rise again increasing metabolic dysfunction-associated steatotic disease alcohol-related disease. The landscape evolving requires a multidisciplinary approach, often involving multi-modal treatments that include surgical resection, transplantation, local regional therapies, systemic treatments. optimal approach care patient team hepatology, medical oncology, diagnostic interventional radiology, radiation surgery. In order determine which best, an individualized plan should consider patient's function, functional status, comorbidities, stage, preferences. this review, we provide overview current options key trials have revolutionized management HCC. We also discuss paradigms for future.

Language: Английский

Citations

38
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma DOI
Bruno Sangro, Lorenza Rimassa, Maxime Ronot

et al.

Journal of Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 1, 2024

Language: Английский

Citations

23
British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults DOI Creative Commons
Abid Suddle, Helen L. Reeves, Richard Hubner

et al.

Gut, Journal Year: 2024, Volume and Issue: 73(8), P. 1235 - 1268

Published: April 16, 2024

Deaths from the majority of cancers are falling globally, but incidence and mortality hepatocellular carcinoma (HCC) is increasing in United Kingdom other Western countries. HCC a highly fatal cancer, often diagnosed late, with an to ratio that approaches 1. Despite there being number treatment options, including those associated good medium long-term survival, 5-year survival UK remains below 20%. Sex, ethnicity deprivation important demographics for of, and/or from, HCC. These clinical practice guidelines will provide evidence-based advice assessment management patients The scientific data underpinning recommendations we make summarised detail. Much content have broad relevance, algorithms based on therapies available regulatory approval use National Health Service.

Language: Английский

Citations

18
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial DOI Creative Commons

Da Xu,

Hongwei Wang, Qun Ma

et al.

Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)

Published: Feb. 7, 2025

This open-label phase II trial (NCT04542837) aimed to evaluate the efficacy and safety of KN046 combined with lenvatinib in patients advanced hepatocellular carcinoma (HCC), explore potential response biomarkers. Participants received 5 mg/kg every 3 weeks 12 or 8 mg once daily. The primary endpoints were safety, tolerability, dose-limiting toxicity (DLT), objective rate (ORR) according RECIST v1.1. A total fifty-five participants enrolled. results meet pre-specified endpoints. No DLT was observed run-in period. incidence serious adverse events grade ≥3 treatment-related (TRAEs) 30.9% 47.3%, respectively. Grade immunotherapy-related occurred (5.5%) participants. Five (9.1%) discontinued treatment due TRAEs, all which 1-2. ORR 45.5% (95% CI, 31.97-59.45). median progression-free survival 11.0 8.21-15.24) months. overall (OS) 16.4 11.20-not estimable) months, 12-month OS 60.0% 45.87-71.55). Circulating tumor DNA status before third cycle associated prognosis. In conclusion, First-line plus shows promising for unresectable metastatic HCC.

Language: Английский

Citations

4
Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers DOI Open Access
Αreti Strati, Christos Adamopoulos, Ioannis Kotsantis

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(3), P. 1235 - 1235

Published: Jan. 31, 2025

The PD1/PD-L1 axis plays an important immunosuppressive role during the T-cell-mediated immune response, which is essential for physiological homeostasis of system. biology immunological microenvironment extremely complex and crucial development treatment strategies immunotherapy. Characterization immunological, genomic or transcriptomic landscape cancer patients could allow discrimination between responders non-responders to anti-PD-1/PD-L1 therapy. Immune checkpoint inhibitor (ICI) therapy has shown remarkable efficacy in a variety malignancies landmark trials fundamentally changed Current research focuses on maximize patient selection therapy, clarify mechanisms resistance, improve existing biomarkers, including PD-L1 expression tumor mutational burden (TMB), discover new biomarkers. In this review, we focus function PD-1/PD-L1 signaling pathway discuss genomic, epigenetic receiving Finally, provide overview clinical testing antibodies against PD-1/PD-L1.

Language: Английский

Citations

2
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up DOI

Arndt Vogel,

S.L. Chan,

Laura A. Dawson

et al.

Annals of Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

2
Immunotherapy for hepatocellular carcinoma DOI Creative Commons

Alexa Childs,

Gloryanne Aidoo-Micah,

Mala K. Maini

et al.

JHEP Reports, Journal Year: 2024, Volume and Issue: 6(10), P. 101130 - 101130

Published: June 13, 2024

Language: Английский

Citations

12
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma DOI Creative Commons
George Lau, Ghassan K. Abou‐Alfa, Ann‐Lii Cheng

et al.

Journal of Hepatology, Journal Year: 2024, Volume and Issue: 82(2), P. 258 - 267

Published: July 31, 2024

Highlights•The HIMALAYA study showed improved outcomes with STRIDE vs. sorafenib in unresectable hepatocellular carcinoma (uHCC).•In an Asian subgroup of HIMALAYA, overall survival and objective response rates sorafenib.•Outcomes were the participants enrolled Hong Kong Taiwan.•Treatment-related adverse events generally manageable low grade subgroup.•STRIDE is beneficial for people uHCC Asia-Pacific region, consistent global population.AbstractBackground & AimsIn global, phase III (uHCC), (Single Tremelimumab Regular Interval Durvalumab) (OS) sorafenib; durvalumab was noninferior to sorafenib. HBV predominant HCC aetiology most Asia HCV or nonviral aetiologies Western countries Japan. This analysis evaluated safety efficacy monotherapy sorafenib, Asia, excluding Japan.MethodsIn randomised STRIDE, durvalumab, The this included Kong, India, South Korea, Taiwan, Thailand, Vietnam. OS, rate (ORR; per Response Evaluation Criteria Solid Tumors, version 1.1), assessed exploratory Taiwan.ResultsThe 479 (n=156), (n=167), (n=156). OS (HR 0.68; 95% CI 0.52-0.89]). HR 0.83 (95% 0.64-1.06). In Taiwan (n=141), HRs 0.44 0.26-0.77) 0.64 0.37-1.08), respectively. subgroup, ORR (including unconfirmed responses) numerically higher (28.2%) (18.6%) (9.0%), Grade 3/4 treatment-related lower (19.9%) (13.3%) (30.5%).ConclusionsSTRIDE subgroup. These results support benefits globally, including region.Clinical trial numberNCT03298451Impact implicationsThe found that regimen (OS), long-term (uHCC). However, there are differences clinical practices related parts compared Japan, which could lead treatment between these regions. demonstrate full, population. Overall, findings continue use a diverse population, reflective globally.Graphical abstract

Language: Английский

Citations

10